Hematopoietic growth factors: ESMO recommendations for the application.

Greil, R; Psenak, O; Ann Oncol. 2007; 18 Suppl 2: ii89-ii91.

The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice

Namberger, K; Greil, R; Imaging decisions (Berlin, Germany). 2007; 10(4): 22-31.

Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.

Steger, GG; Galid, A; Gnant, M; Mlineritsch, B; Lang, A; Tausch, C; Rudas, M; Greil, R; Wenzel, C; Singer, CF; Haid, A; Postlberger, S; Samonigg, H; Luschin-Ebengreuth, G; Kwasny, W; Klug, E; Kubista, E; Menzel, C; Jakesz, R J CLIN ONCOL. 2007; 25(15): 2012-2018.

Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

Gnant, MFX; Mlineritsch, B; Luschin-Ebengreuth, G; Grampp, S; Kaessmann, H; Schmid, M; Menzel, C; Piswanger-Soelkner, JC; Galid, A; Mittlboeck, M; Hausmaninger, H; Jakesz, R J Clin Oncol. 2007; 25(7):820-828

IMMUNOMODULATORY CAPACITY OF MYELOMA-DERIVED CHEMOKINE CCL27

Johrer, K; Olivier, A; Unger, M; Maizner, E; Neureiter, D; Greil, R ANTICANCER RES. 2008; 28(5C): 3336-3337.

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.

Egle, A; Weiss, L; Gassner, F; Russ, G; Pleyer, L; Gunsilius, E; Tinhofer, I; Thaler, J; Petzer, AL; Greil, R BLOOD. 2008; 112(11): 1089-1089.

MULTIPLE MYELOMA – CHEMOKINE NETWORK: CCL27/CTACK – A NEW PLAYER IN MYELOMA PROGRESSION

Olivier, A; Unger, M; Maizner, E; Neureiter, D; Greil, R; Johrer, K ANTICANCER RES. 2008; 28(5C): 3429-3429.

The single nucleotide polymorphism MDM2-SNP309 influences sensitivity of B-CLL cells to the non-genotoxic activator of the p53 pathway Nutlin-3a

Tinhofer, I; Seyfried, I; Stoecher, M; Hofbauer, S; Daniel, PT; Greil, R J CLIN ONCOL. 2008; 26(15):

Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.

Borchmann, P; Engert, A; Pluetschow, A; Fuchs, M; Markova, J; Lohri, A; Kral, Z; Greil, R; Topp, M; Villalobos, M; Zijlstra, J; Soekler, M; Stein, H; Eich, HT; Mueller, RP; Diehl, V; Blood. 2008; 112(11):367–50th Annual Meeting of American Society of Hematology (ASH); 06.-09.12.2008; San Francisco, California.

ZOLEDRONIC ACID (ZOL) IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (ERBC) RECEIVING ADJUVANT ENDOCRINE THERAPY: MULTIVARIATE ANALYSIS OF EFFICACY DATA FROM THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12

Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, GG; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R ANN ONCOL. 2008; 19: 44-44.